261 related articles for article (PubMed ID: 29151258)
1. Clinical significance of disease-specific MYD88 mutations in circulating DNA in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Suehara Y; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Hasegawa Y; Chiba S
Cancer Sci; 2018 Jan; 109(1):225-230. PubMed ID: 29151258
[TBL] [Abstract][Full Text] [Related]
2. The use of droplet digital PCR in liquid biopsies: A highly sensitive technique for MYD88 p.(L265P) detection in cerebrospinal fluid.
Hiemcke-Jiwa LS; Minnema MC; Radersma-van Loon JH; Jiwa NM; de Boer M; Leguit RJ; de Weger RA; Huibers MMH
Hematol Oncol; 2018 Apr; 36(2):429-435. PubMed ID: 29210102
[TBL] [Abstract][Full Text] [Related]
3. Detection of circulating tumor DNA in plasma of patients with primary CNS lymphoma by digital droplet PCR.
Zhong Y; Tan GW; Bult J; Veltmaat N; Plattel W; Kluiver J; Enting R; Diepstra A; van den Berg A; Nijland M
BMC Cancer; 2024 Apr; 24(1):407. PubMed ID: 38566053
[TBL] [Abstract][Full Text] [Related]
4. Rapid detection of the MYD88 L265P mutation for pre- and intra-operative diagnosis of primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Kitano Y; Maeda S; Motomura K; Aoki K; Takeuchi K; Nagata Y; Hattori H; Tsujiuchi T; Motomura A; Nishikawa T; Kibe Y; Shinjo K; Kondo Y; Saito R
Cancer Sci; 2023 Jun; 114(6):2544-2551. PubMed ID: 36859777
[TBL] [Abstract][Full Text] [Related]
5. Genetic evidence implies that primary and relapsed tumors arise from common precursor cells in primary central nervous system lymphoma.
Hattori K; Sakata-Yanagimoto M; Kusakabe M; Nanmoku T; Suehara Y; Matsuoka R; Noguchi M; Yokoyama Y; Kato T; Kurita N; Nishikii H; Obara N; Takano S; Ishikawa E; Matsumura A; Muratani M; Hasegawa Y; Chiba S
Cancer Sci; 2019 Jan; 110(1):401-407. PubMed ID: 30353605
[TBL] [Abstract][Full Text] [Related]
6. Liquid biopsy of cerebrospinal fluid for MYD88 L265P mutation is useful for diagnosis of central nervous system lymphoma.
Yamagishi Y; Sasaki N; Nakano Y; Matushita Y; Omura T; Shimizu S; Saito K; Kobayashi K; Narita Y; Kondo A; Shiokawa Y; Nagane M; Ichimura K
Cancer Sci; 2021 Nov; 112(11):4702-4710. PubMed ID: 34523186
[TBL] [Abstract][Full Text] [Related]
7. Highly sensitive
Drandi D; Genuardi E; Dogliotti I; Ferrante M; Jiménez C; Guerrini F; Schirico ML; Mantoan B; Muccio V; Lia G; Zaccaria GM; Omedè P; Passera R; Orsucci L; Benevolo G; Cavallo F; Galimberti S; Sanz RG; Boccadoro M; Ladetto M; Ferrero S
Haematologica; 2018 Jun; 103(6):1029-1037. PubMed ID: 29567768
[TBL] [Abstract][Full Text] [Related]
8. MYD88 L265P mutation and interleukin-10 detection in cerebrospinal fluid are highly specific discriminating markers in patients with primary central nervous system lymphoma: results from a prospective study.
Ferreri AJM; Calimeri T; Lopedote P; Francaviglia I; Daverio R; Iacona C; Belloni C; Steffanoni S; Gulino A; Anghileri E; Diffidenti A; Finardi A; Gagliardi F; Anzalone N; Nonis A; Furlan R; De Lorenzo D; Terreni MR; Martinelli V; Sassone M; Foppoli M; Angelillo P; Guggiari E; Falini A; Mortini P; Filippi M; Tarantino V; Eoli M; Ciceri F; Doglioni C; Tripodo C; Locatelli M; Cangi MG; Ponzoni M
Br J Haematol; 2021 May; 193(3):497-505. PubMed ID: 33620087
[TBL] [Abstract][Full Text] [Related]
9. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction.
Hiemcke-Jiwa LS; Ten Dam-van Loon NH; Leguit RJ; Nierkens S; Ossewaarde-van Norel J; de Boer JH; Roholl FF; de Weger RA; Huibers MMH; de Groot-Mijnes JDF; Kuiper JJW
JAMA Ophthalmol; 2018 Oct; 136(10):1098-1104. PubMed ID: 30027272
[TBL] [Abstract][Full Text] [Related]
10. MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring : ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation.
Drandi D; Ferrante M; Borriero M; Ferrero S
Methods Mol Biol; 2023; 2621():57-72. PubMed ID: 37041440
[TBL] [Abstract][Full Text] [Related]
11. Prognostic value of MYD88 L265P mutation in diffuse large B cell lymphoma via droplet digital PCR.
Niu J; Ma Z; Nuerlan A; Li S; Cui W; Gao H; Abulajiang G; Zhang W; Li X
Mol Med Rep; 2020 Aug; 22(2):1243-1256. PubMed ID: 32468019
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness of digital PCR for MYD88
Chen K; Ma Y; Ding T; Zhang X; Chen B; Guan M
Exp Ther Med; 2020 Jul; 20(1):301-308. PubMed ID: 32536998
[TBL] [Abstract][Full Text] [Related]
13. MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis.
Takano S; Hattori K; Ishikawa E; Narita Y; Iwadate Y; Yamaguchi F; Nagane M; Akimoto J; Oka H; Tanaka S; Sakata M; Matsuda M; Yamamoto T; Chiba S; Matsumura A
World Neurosurg; 2018 Apr; 112():e69-e73. PubMed ID: 29258950
[TBL] [Abstract][Full Text] [Related]
14. Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
Montesinos-Rongen M; Brunn A; Tuchscherer A; Borchmann P; Schorb E; Kasenda B; Altmüller J; Illerhaus G; Ruge MI; Maarouf M; Büttner R; Hansmann ML; Hallek M; Prinz M; Siebert R; Deckert M
J Mol Diagn; 2020 Oct; 22(10):1300-1307. PubMed ID: 32745612
[TBL] [Abstract][Full Text] [Related]
15. MYD88 L265P mutation detected by digital PCR as a prognostic factor in patients with diffuse large B-cell lymphoma in rituximab era.
Nishimura N; Takeuchi K; Asaka R; Tuyama N; Inoue N; Kusano Y; Mishima Y; Yokoyama M; Terui Y
Leuk Res; 2020 Oct; 97():106426. PubMed ID: 32781214
[TBL] [Abstract][Full Text] [Related]
16. Clinical Relevance of the High Prevalence of MYD88 L265P Mutated Vitreoretinal Lymphoma Identified by Droplet Digital Polymerase Chain Reaction.
Shi H; Zhou X; Chen B; Xiao J; Li Y; Zhou X; Zhou Q; Chen K; Wang Q
Ocul Immunol Inflamm; 2021 Apr; 29(3):448-455. PubMed ID: 31603365
[No Abstract] [Full Text] [Related]
17. Detection of the
Zorofchian S; Lu G; Zhu JJ; Duose DY; Windham J; Esquenazi Y; Ballester LY
Front Oncol; 2018; 8():382. PubMed ID: 30294590
[TBL] [Abstract][Full Text] [Related]
18.
Nayyar N; White MD; Gill CM; Lastrapes M; Bertalan M; Kaplan A; D'Andrea MR; Bihun I; Kaneb A; Dietrich J; Ferry JA; Martinez-Lage M; Giobbie-Hurder A; Borger DR; Rodriguez FJ; Frosch MP; Batchelor E; Hoang K; Kuter B; Fortin S; Holdhoff M; Cahill DP; Carter S; Brastianos PK; Batchelor TT
Blood Adv; 2019 Feb; 3(3):375-383. PubMed ID: 30723112
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic significance of MYD88 L265P mutation and expression of TLR4 and P-STAT3 in primary central nervous system diffuse large B-cell lymphomas.
Tang D; Su W; Wang X; Chu Z; Zhang L; Zhou J; Zhang Q
Brain Tumor Pathol; 2021 Jan; 38(1):50-58. PubMed ID: 33079297
[TBL] [Abstract][Full Text] [Related]
20. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma.
Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R
Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
